Multiple patient batch production of 195mPt cisplatin and 195mPt carboplatin for use in drug risk assessment and optimisation of patient dose

Simple item page
dc.contributor.authorPerkins, Gen_AU
dc.contributor.authorSmith, SVen_AU
dc.date.accessioned2014-12-22T04:20:53Zen_AU
dc.date.available2014-12-22T04:20:53Zen_AU
dc.date.issued2010-08-01en_AU
dc.date.statistics2014-12-22en_AU
dc.description.abstractPlatinum chemotherapeutics are used extensively as a first line treatment in over 28% of all cancers and widely as a second line treatment in combination with biological markers such as Herceptin. Over 20% of patients will experience maximum tolerate dose and significant side effects because dosage is often estimated using unreliable and indirect methods such as surface area and glomerular filtration rates. We are interested in providing a molecular imaging tool that allows the physician to screen a patient, monitor response and drug resistance and to personalise treatment regimes in order to reduce side effects. The ability to produce platinum radiopharmaceuticals commercially has been limited by long and unreliable synthetic processes. We have developed patent technology for the production of reactor base platinum radiopharmaceuticals, such as 195mPt-cisplatin and 195mPt-carboplatin. This study reports the neutron activation of 194platinum target material in the new research reactor OPAL and validation of the production of multiple (five) patient batches for both 195mcisplatin and 195mcarbplatin. Yields were 53±3% and 29±4%, respectively, with specific activities of up to 8MBq/mg. Production times were dramatically reduced from up to 24 h to less than 3 h using the new process.© 2010, Elsevier Ltd.en_AU
dc.identifier.citationPerkins, G., & Smith, S.V. (2010). Multiple patient batch production of 195mpt cisplatin and 195mpt carboplatin for use in drug risk assessment and optimisation of patient dose. Nuclear Medicine and Biology, 37(6), 726. doi:10.1016/j.nucmedbio.2010.04.145en_AU
dc.identifier.govdoc5683en_AU
dc.identifier.issn0969-8051en_AU
dc.identifier.issue6en_AU
dc.identifier.journaltitleNuclear Medicine and Biologyen_AU
dc.identifier.pagination726en_AU
dc.identifier.urihttp/dx.doi.org/10.1016/j.nucmedbio.2010.04.145en_AU
dc.identifier.urihttp://apo.ansto.gov.au/dspace/handle/10238/6100en_AU
dc.identifier.volume37en_AU
dc.language.isoenen_AU
dc.publisherElsevier Scienceen_AU
dc.subjectPatientsen_AU
dc.subjectNeoplasmsen_AU
dc.subjectFiltrationen_AU
dc.subjectHuman populationsen_AU
dc.subjectMonitoringen_AU
dc.subjectToleranceen_AU
dc.titleMultiple patient batch production of 195mPt cisplatin and 195mPt carboplatin for use in drug risk assessment and optimisation of patient doseen_AU
dc.typeJournal Articleen_AU
Files
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Journal Articles